What Do Investors Think About Geron Corporation (GERN) Following Q2 Results?

Geron Corporation (NASDAQ:GERN) is one of the best long-term penny stocks to buy right now. Geron Corporation (NASDAQ:GERN) reported its fiscal Q2 2025 results on August 6, announcing $49.0 million in RYTELO net product revenue in the quarter.

Management also reported that the Phase 3 IMpactMF clinical trial in relapsed/refractory myelofibrosis is over 95% enrolled and is anticipated to be fully enrolled by year-end.

On August 15, Leerink Partners analyst Faisal Khurshid reiterated a Buy rating on Geron Corporation (NASDAQ:GERN), keeping the associated price target the same at $3.00.

In another report released on August 7, Barclays also maintained a Buy rating on Geron Corporation (NASDAQ:GERN) with a $4.00 price target.

The stock’s median price target of $1.43 implies an upside of 179.72% from current levels.

Geron Corporation (NASDAQ:GERN) is a biotechnology company that develops Imetelstat, a telomerase inhibitor in hematologic myeloid malignancies. It focuses on oncology-focused therapeutic products.

While we acknowledge the potential of GERN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.